X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10687) 10687
Book Chapter (80) 80
Dissertation (24) 24
Publication (15) 15
Conference Proceeding (6) 6
Magazine Article (6) 6
Newspaper Article (6) 6
Web Resource (4) 4
Government Document (3) 3
Streaming Video (3) 3
Book / eBook (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6060) 6060
immunology (3742) 3742
animals (3686) 3686
ctla-4 (3613) 3613
ctla-4 antigen (3094) 3094
immunotherapy (2938) 2938
female (2725) 2725
mice (2487) 2487
male (2369) 2369
oncology (2282) 2282
cancer (1959) 1959
antigens, cd (1717) 1717
ctla-4 protein (1698) 1698
lymphocytes (1582) 1582
melanoma (1576) 1576
abatacept (1567) 1567
expression (1565) 1565
t cells (1533) 1533
ipilimumab (1386) 1386
middle aged (1381) 1381
immunoconjugates (1362) 1362
t-lymphocytes - immunology (1347) 1347
adult (1332) 1332
lymphocytes t (1324) 1324
ctla-4 blockade (1134) 1134
activation (1114) 1114
antigens (1109) 1109
ctla-4 antigen - immunology (1013) 1013
cd28 (1001) 1001
pd-1 (989) 989
tumors (973) 973
antibodies, monoclonal - therapeutic use (956) 956
aged (922) 922
dendritic cells (911) 911
t-cells (903) 903
ctla-4 antigen - antagonists & inhibitors (902) 902
immune checkpoint (875) 875
lymphocyte activation (862) 862
mice, inbred c57bl (839) 839
metastatic melanoma (826) 826
medicine, research & experimental (824) 824
cytotoxicity (823) 823
antigens, differentiation - genetics (815) 815
t-lymphocytes, regulatory - immunology (813) 813
research (782) 782
care and treatment (779) 779
autoimmunity (764) 764
immunotherapy - methods (758) 758
antigens, differentiation - immunology (726) 726
regulatory t-cells (724) 724
apoptosis (716) 716
mice, inbred balb c (699) 699
chemical and pharmacologic phenomena (695) 695
flow cytometry (694) 694
nivolumab (687) 687
antigens, cd - immunology (676) 676
ctla-4 antigen - genetics (676) 676
neoplasms - immunology (675) 675
immune system (672) 672
analysis (669) 669
patients (650) 650
genetic aspects (648) 648
in-vivo (647) 647
immune response (637) 637
cd4-positive t-lymphocytes - immunology (636) 636
blockade (633) 633
genetic predisposition to disease (628) 628
cell biology (626) 626
programmed cell death 1 receptor - antagonists & inhibitors (622) 622
gene expression (616) 616
therapy (595) 595
cytokines (594) 594
pd-1 protein (586) 586
cells, cultured (582) 582
ctla-4 antigen - metabolism (576) 576
antigens, cd - genetics (574) 574
transplantation (573) 573
metastasis (572) 572
susceptibility (569) 569
melanoma - drug therapy (566) 566
receptor (566) 566
chemotherapy (558) 558
antigen (555) 555
antibodies (554) 554
induction (551) 551
genotype (546) 546
health aspects (544) 544
costimulation (538) 538
biochemistry & molecular biology (532) 532
disease (522) 522
treatment outcome (518) 518
ligands (517) 517
tolerance (515) 515
pd-1 blockade (506) 506
survival (502) 502
cd8-positive t-lymphocytes - immunology (490) 490
multidisciplinary sciences (490) 490
antigens, cd - metabolism (489) 489
neoplasms - therapy (483) 483
responses (481) 481
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10424) 10424
Chinese (111) 111
Japanese (87) 87
French (86) 86
German (71) 71
Polish (27) 27
Spanish (21) 21
Russian (17) 17
Czech (12) 12
Korean (11) 11
Hungarian (6) 6
Portuguese (5) 5
Turkish (5) 5
Danish (4) 4
Persian (3) 3
Swedish (3) 3
Dutch (2) 2
Finnish (2) 2
Hebrew (1) 1
Italian (1) 1
Norwegian (1) 1
Romanian (1) 1
Slovak (1) 1
Slovenian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature (London), ISSN 1476-4687, 2017, Volume 551, Issue 7681, pp. 517 - 520
Checkpoint blockade immunotherapies enable the host immune system to recognize and destroy tumour cells(1). Their clinical activity has been correlated with... 
CELL LUNG-CANCER | CTLA-4 BLOCKADE | MELANOMA | THERAPY | LANDSCAPE | PD-1 BLOCKADE | MULTIDISCIPLINARY SCIENCES | SENSITIVITY | RESISTANCE | CLINICAL-RESPONSE | REPERTOIRES | Humans | Lung Neoplasms - pathology | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antigen Presentation | Melanoma - genetics | Immunotherapy | Cell Cycle Checkpoints - genetics | Cell Cycle Checkpoints - immunology | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Antigens, Neoplasm - genetics | Antigens, Neoplasm - immunology | Carcinoma, Non-Small-Cell Lung - genetics | Lymphocyte Activation | CTLA-4 Antigen - genetics | Lung Neoplasms - therapy | Melanoma - pathology | CTLA-4 Antigen - immunology | Carcinoma, Non-Small-Cell Lung - immunology | Carcinoma, Non-Small-Cell Lung - therapy | Lung Neoplasms - immunology | Models, Immunological | Melanoma - immunology | Survival Analysis | T-Lymphocytes - immunology | Programmed Cell Death 1 Receptor - immunology | CTLA-4 Antigen - antagonists & inhibitors | Melanoma - therapy | Programmed Cell Death 1 Receptor - genetics | Cohort Studies | Evolution, Molecular | Antigens | Care and treatment | Patient outcomes | Models | Health aspects | Tumors | Medical research | Peptides | PD-1 protein | Lung cancer | Melanoma | Cytotoxicity | Lymphocytes T | Patients | Proteins | Cell recognition | CTLA-4 protein | Major histocompatibility complex | Immune checkpoint | Lymphocytes | Evolution | Mutation | Cancer | Immune system | Fitness
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2013, Volume 369, Issue 2, pp. 122 - 133
Journal Article
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 54, pp. 139 - 148
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2015, Volume 112, Issue 2, pp. 524 - 529
Journal Article
Trends in Molecular Medicine, ISSN 1471-4914, 2015, Volume 21, Issue 8, pp. 482 - 491
Highlights • Immune checkpoints dampen T cell activation, avoiding excessive immune responses. • CTLA-4 and PD-1 are currently the two most clinically relevant... 
Pathology | checkpoint blockade | MDSCs | CTLA-4 | PD-1 | cancer immunotherapy | Cancer immunotherapy | Checkpoint blockade | MEDICINE, RESEARCH & EXPERIMENTAL | CTLA-4 BLOCKADE | SOLID TUMORS | ADVANCED MELANOMA PATIENTS | BIOCHEMISTRY & MOLECULAR BIOLOGY | SPONTANEOUS REGRESSION | CELL BIOLOGY | METASTATIC MELANOMA | LUNG-CANCER | ANTI-PD-L1 ANTIBODY | REGULATORY T-CELLS | CLINICAL-RESPONSE | ADVERSE EVENTS | Neoplasms - metabolism | T-Lymphocyte Subsets - immunology | Humans | Immunosuppressive Agents - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Neoplasms - therapy | Neoplasms - genetics | Myeloid Cells - immunology | Cancer Vaccines | Immunotherapy | Antineoplastic Agents - pharmacology | Immunosuppressive Agents - pharmacology | CTLA-4 Antigen - metabolism | Programmed Cell Death 1 Receptor - metabolism | Treatment Outcome | Combined Modality Therapy | CTLA-4 Antigen - immunology | Radiotherapy | Immunosuppression | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms - immunology | T-Lymphocyte Subsets - metabolism | Myeloid Cells - metabolism | Ligands | CTLA-4 Antigen - antagonists & inhibitors | Antimitotic agents | Care and treatment | Antineoplastic agents | Health aspects | Cancer | Immune system
Journal Article